Research, discovery, and translation to practice are at the core of the mission for the George Washington University School of Medicine and Health Sciences. By accelerating research excellence, enhancing innovation, and advancing translation, our goal is to make discoveries and improve clinical care.
The scientific workforce, composed of highly educated researchers and scientists-in training, clinician investigators, as well as skilled technical support staff, project managers, and core team members, together contribute to research discovery. Training the next generation of biomedical scientists is a key goal.
Funding and support, obtained from federal and non-federal grants and contracts, private industry investment, and philanthropy, is essential to sustain our research programs. SMHS provides funding opportunities and strategies to gain support.
With a five-year, $6.2 million project program grant, researchers at the George Washington University School of Medicine and Health Sciences have begun to crack open the mystery behind 22q11.2 Deletion Syndrome, or DiGeorge Syndrome.
More than 150 MD program students presented abstracts, poster sessions, and selected oral presentations on a range of disciplines, such as clinical and translational science, clinical public health, and medical education-related research.
The GW School of Medicine and Health Sciences has been selected to serve as one of 24 participating sites for the Phase 2 clinical trial to evaluate additional COVID-19 booster shots in adults, including multiple vaccines based on viral variants such as Delta and Omicron. The trial aims to understand if different vaccine regimens – prototype and variant vaccines alone and in combinations – can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot.